Literature DB >> 12030606

Blood coagulation and fibrinolysis in patients with hyperthyroidism.

C Erem1, H O Ersoz, S S Karti, K Ukinç, A Hacihasanoglu, O Değer, M Telatar.   

Abstract

Several papers concerning abnormalities of blood coagulation and fibrinolysis during hyperthyroidism, have been published. Increased von Willebrand Factor (vWF) activity and high fibrinogen levels have been reported. However, there is controversy concerning the presence of a hypercoagulable state in hyperthyroidism. We investigated various hemostatic parameters in 41 hyperthyroid patients and compared them to 20 euthyroid controls. Prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factors V, VII, VIII, IX and X activities, vWF, antithrombin III (AT III), protein C, protein S, tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor-1 (PAI-1), as well as common lipid variables, were measured. The relationships between serum thyroid hormones and these hemostatic parameters were examined. Compared with control subjects, fibrinogen, factor IX, vWF, AT III and PAI-1 were significantly increased in patients (p<0.05, p<0.0001, p<0.05, p<0.01 and p<0.0001; respectively), whereas factor X and t-PA were decreased (p<0.05). We showed that free T4 (FT3) levels were correlated with factor VIII activity (r=0.35, p<0.05). FT4, FT3 and TSH did not correlate with fibrinogen, vWF, AT III, t-PA, or PAI-1. AT III was inversely correlated with factor VII activity (r=-0.48, p<0.01). Protein C and S were correlated with vWF levels (r=0.58, p<0.0001; r=0.55, p<0.0001, respectively). Protein C was inversely correlated with t-PA (r=-0.39, p<0.01). There was a negative correlation between triglycerides, LDL-C and F X (r=-0.45, p<0.05; r=-64, p<0.01, respectively). Mean platelet volume (MPV) was correlated with anti-thyroid peroxidase (TPO) antibodies (in Graves'disease) and F IX activity (r=0.57, p<0.05 and r=0.39, p<0.05; respectively). We found important differences in the coagulatory /fibrinolytic parameters between the hyperthyroid patients and healthy controls. Hyperthyroid patients may experience vascular endothelial dysfunction and decreased fibrinolytic activity in blood. This endothelial activation may represent a situation with a higher thromboembolic potential.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12030606     DOI: 10.1007/BF03344016

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

1.  THE BIOLOGICAL DISAPPEARANCE RATE OF PROTHROMBIN, FACTORS VII, IX AND X FROM PLASMA IN HYPOTHYROIDISM, HYPERTHYROIDISM, AND DURING FEVER.

Authors:  E A LOELIGER; B VAN DER ESCH; M J MATTERN; H C HEMKER
Journal:  Thromb Diath Haemorrh       Date:  1964-01-01

2.  Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease.

Authors:  E Morishita; T Hashimoto; H Asakura; M Saito; M Yamazaki; K Aoshima; T Yoshida; H Kato; T Matsuda
Journal:  Thromb Haemost       Date:  1998-05       Impact factor: 5.249

3.  Acquired von Willebrand's disease in hypothyroidism.

Authors:  H Takahashi; M Yamada; A Shibata
Journal:  Thromb Haemost       Date:  1987-12-18       Impact factor: 5.249

4.  Features of endothelial dysfunction in early diabetic nephropathy.

Authors:  T Jensen; J Bjerre-Knudsen; B Feldt-Rasmussen; T Deckert
Journal:  Lancet       Date:  1989-03-04       Impact factor: 79.321

5.  Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol.

Authors:  J Burggraaf; S Lalezari; J J Emeis; U M Vischer; P H de Meyer; H Pijl; A F Cohen
Journal:  Thyroid       Date:  2001-02       Impact factor: 6.568

6.  Assessment of endothelial function during oral contraception in women with insulin-dependent diabetes mellitus.

Authors:  K R Petersen; S O Skouby; J Sidelmann; J Jespersen
Journal:  Metabolism       Date:  1994-11       Impact factor: 8.694

7.  Activation of blood coagulation and fibrinolysis in Graves' disease.

Authors:  F Marongiu; M Conti; M L Murtas; G Mameli; G G Sorano; E Martino
Journal:  Horm Metab Res       Date:  1991-12       Impact factor: 2.936

8.  Factor VIII activity and thyroid function.

Authors:  J S Rogers; S R Shane; F S Jencks
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

9.  Effect of thyroid hormones on plasma protein concentrations in man.

Authors:  W Graninger; K R Pirich; W Speiser; E Deutsch; W K Waldhäusl
Journal:  J Clin Endocrinol Metab       Date:  1986-08       Impact factor: 5.958

10.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

Authors:  A Hamsten; B Wiman; U de Faire; M Blombäck
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

View more
  37 in total

Review 1.  Thyroid-associated autoimmune coagulation disorders.

Authors:  Massimo Franchini; Giuseppe Lippi; Franco Manzato; Pier Paolo Vescovi
Journal:  J Thromb Thrombolysis       Date:  2009-03-10       Impact factor: 2.300

Review 2.  Embolic risk in atrial fibrillation that arises from hyperthyroidism: review of the medical literature.

Authors:  Elie Traube; Neil L Coplan
Journal:  Tex Heart Inst J       Date:  2011

3.  Plateletcrit. A platelet marker associated with saphenous vein graft disease.

Authors:  I Akpinar; M R Sayin; Y C Gursoy; T Karabag; E Kucuk; M C Buyukuysal; M Aydin; I C Haznedaroglu
Journal:  Herz       Date:  2013-04-12       Impact factor: 1.443

4.  Endothelial dysfunction in subjects with subclinical hyperthyroidism.

Authors:  E Coban; M Aydemir; G Yazicioglu; M Ozdogan
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

5.  Utility of plasma fibrinogen in the differential diagnosis of thyrotoxicosis.

Authors:  Jie Ma; Rui Liu; Di Wu; Wei Miao; Qian Chen; Yushu Li; Haixia Guan
Journal:  Int J Clin Exp Med       Date:  2015-01-15

6.  Proteomics Profiling of the Urine of Patients with Hyperthyroidism after Anti-Thyroid Treatment.

Authors:  Hicham Benabdelkamel; Afshan Masood; Aishah A Ekhzaimy; Assim A Alfadda
Journal:  Molecules       Date:  2021-04-01       Impact factor: 4.411

7.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.

Authors:  Cihangir Erem; Ozge Ucuncu; Mustafa Yilmaz; Mustafa Kocak; Irfan Nuhoglu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2008-10-29       Impact factor: 3.633

Review 8.  Thyroid, hemostasis and thrombosis.

Authors:  F Marongiu; C Cauli; S Mariotti
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

9.  Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients.

Authors:  Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Gian Luca Salvagno; Gian Cesare Guidi; Emmanuel J Favaloro
Journal:  J Thromb Thrombolysis       Date:  2008-09-12       Impact factor: 2.300

10.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.

Authors:  Cihangir Erem; Ozge Ucuncu; Mustafa Yilmaz; Mustafa Kocak; İrfan Nuhoglu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2009-10-27       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.